SG11201805363QA - Drug comprising aripiprazole and cilostazol - Google Patents
Drug comprising aripiprazole and cilostazolInfo
- Publication number
- SG11201805363QA SG11201805363QA SG11201805363QA SG11201805363QA SG11201805363QA SG 11201805363Q A SG11201805363Q A SG 11201805363QA SG 11201805363Q A SG11201805363Q A SG 11201805363QA SG 11201805363Q A SG11201805363Q A SG 11201805363QA SG 11201805363Q A SG11201805363Q A SG 11201805363QA
- Authority
- SG
- Singapore
- Prior art keywords
- international
- cilostazol
- aripiprazole
- busan
- pct
- Prior art date
Links
- RRGUKTPIGVIEKM-UHFFFAOYSA-N cilostazol Chemical compound C=1C=C2NC(=O)CCC2=CC=1OCCCCC1=NN=NN1C1CCCCC1 RRGUKTPIGVIEKM-UHFFFAOYSA-N 0.000 title abstract 5
- CEUORZQYGODEFX-UHFFFAOYSA-N Aripirazole Chemical compound ClC1=CC=CC(N2CCN(CCCCOC=3C=C4NC(=O)CCC4=CC=3)CC2)=C1Cl CEUORZQYGODEFX-UHFFFAOYSA-N 0.000 title abstract 4
- 229960004372 aripiprazole Drugs 0.000 title abstract 4
- 229960004588 cilostazol Drugs 0.000 title abstract 4
- 229940079593 drug Drugs 0.000 title abstract 2
- 239000003814 drug Substances 0.000 title abstract 2
- 102220240796 rs553605556 Human genes 0.000 abstract 5
- 208000028698 Cognitive impairment Diseases 0.000 abstract 2
- 206010012289 Dementia Diseases 0.000 abstract 2
- 208000031889 Vascular Depression Diseases 0.000 abstract 2
- 208000010877 cognitive disease Diseases 0.000 abstract 2
- 230000002265 prevention Effects 0.000 abstract 2
- 241001590997 Moolgarda engeli Species 0.000 abstract 1
- 239000003795 chemical substances by application Substances 0.000 abstract 1
- 230000008520 organization Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Psychiatry (AREA)
- Epidemiology (AREA)
- Hospice & Palliative Care (AREA)
- Pain & Pain Management (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization International Bureau (43) International Publication Date 29 June 2017 (29.06.2017) WIPOIPCT (10) International Publication Number WO 2017/111123 A1 (51) International Patent Classification: A61K31/496 (2006.01) A61P 25/16 (2006.01) A61K 31/4709 (2006.01) A61P 25/24 (2006.01) A61P 9/10 (2006.01) A61P 25/28 (2006.01) A61P 25/14 (2006.01) (21) International Application Number: PCT/JP2016/088554 (22) International Filing Date: (25) Filing Language: (26) Publication Language: 22 December 2016 (22.12.2016) English English (30) Priority Data: PCT/JP2015/006489 25 December 2015 (25.12.2015) JP (71) Applicant: OTSUKA PHARMACEUTICAL CO., LTD. [JP/JP]; 2-9, Kanda Tsukasa-machi, Chiyoda-ku, Tokyo, 1018535 (JP). (72) Inventors: SHIN, Hwa Kyoung; LG metrocity Apt. 134- 902, Bunpo-ro 111, Nam-gu, Busan, 48516 (KR). CHOI, Byung Tae; Ssangyong Apt. 105-2003, Sulim-ro 25, Kumjeong-gu, Busan, 46276 (KR). HONG, Ki Whan; Hy undai Home-town 210-dong 1102-Ho, 16 Bubwone Buk- Ro, Yeoun Je-Ku, Busan, 47508 (KR). (74) Agent: SAEGUSA & PARTNERS; Kitahama TNK Building, 1-7-1, Doshomachi, Chuo-ku, Osaka-shi, Osaka, 5410045 (JP). (81) Designated States (unless otherwise indicated, for every kind of national protection available)'. AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW. (84) Designated States (unless otherwise indicated, for every kind of regional protection available)'. ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG). Published: — with international search report (Art. 21(3)) CJ o CJ (54) Title: DRUG COMPRISING ARIPIPRAZOLE AND CILOSTAZOL (57) : The present invention enables treatment and/or prevention of dementia, cognitive impairment, and vascular depres sion by a combination of aripiprazole and cilostazol, or the like. The combination contains aripiprazole and cilostazol, and is used for the treatment and/or prevention of at least one member selected from the group consisting of dementia, cognitive impairment, and vascular depression.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2015006489 | 2015-12-25 | ||
| PCT/JP2016/088554 WO2017111123A1 (en) | 2015-12-25 | 2016-12-22 | Drug comprising aripiprazole and cilostazol |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG11201805363QA true SG11201805363QA (en) | 2018-07-30 |
Family
ID=59090570
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11201805363QA SG11201805363QA (en) | 2015-12-25 | 2016-12-22 | Drug comprising aripiprazole and cilostazol |
Country Status (14)
| Country | Link |
|---|---|
| US (1) | US20190008854A1 (en) |
| EP (1) | EP3393476A1 (en) |
| JP (1) | JP2018538344A (en) |
| KR (1) | KR20180097652A (en) |
| CN (1) | CN108430474A (en) |
| AU (1) | AU2016375724A1 (en) |
| BR (1) | BR112018012903A2 (en) |
| CA (1) | CA3009309A1 (en) |
| MX (1) | MX2018007791A (en) |
| PH (1) | PH12018501315A1 (en) |
| RU (1) | RU2018127013A (en) |
| SG (1) | SG11201805363QA (en) |
| TW (1) | TW201729809A (en) |
| WO (1) | WO2017111123A1 (en) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN112107579A (en) * | 2019-06-21 | 2020-12-22 | 澳门大学 | Application of aripiprazole in anti-aging |
| JPWO2021230131A1 (en) * | 2020-05-11 | 2021-11-18 | ||
| CN114762688B (en) * | 2021-01-13 | 2024-07-05 | 南京宁丹新药技术有限公司 | Application of cilostazol-containing composition in cerebrovascular diseases |
| WO2022270663A1 (en) * | 2021-06-23 | 2022-12-29 | 동아에스티 주식회사 | Pharmaceutical composition comprising donepezil, cilostazol, and aripiprazole for prevention, alleviation, or treatment of dementia, cognitive impairment, or vascular depression |
Family Cites Families (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP5715303B2 (en) * | 2012-06-15 | 2015-05-07 | 公益財団法人先端医療振興財団 | Preventive and / or therapeutic agent for mild cognitive impairment |
-
2016
- 2016-12-22 CA CA3009309A patent/CA3009309A1/en not_active Abandoned
- 2016-12-22 BR BR112018012903A patent/BR112018012903A2/en not_active IP Right Cessation
- 2016-12-22 JP JP2018532799A patent/JP2018538344A/en active Pending
- 2016-12-22 US US16/064,786 patent/US20190008854A1/en not_active Abandoned
- 2016-12-22 AU AU2016375724A patent/AU2016375724A1/en not_active Abandoned
- 2016-12-22 MX MX2018007791A patent/MX2018007791A/en unknown
- 2016-12-22 EP EP16879009.5A patent/EP3393476A1/en not_active Withdrawn
- 2016-12-22 RU RU2018127013A patent/RU2018127013A/en not_active Application Discontinuation
- 2016-12-22 SG SG11201805363QA patent/SG11201805363QA/en unknown
- 2016-12-22 KR KR1020187020456A patent/KR20180097652A/en unknown
- 2016-12-22 CN CN201680075691.9A patent/CN108430474A/en active Pending
- 2016-12-22 WO PCT/JP2016/088554 patent/WO2017111123A1/en active Application Filing
- 2016-12-23 TW TW105143058A patent/TW201729809A/en unknown
-
2018
- 2018-06-20 PH PH12018501315A patent/PH12018501315A1/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| RU2018127013A (en) | 2020-01-27 |
| WO2017111123A1 (en) | 2017-06-29 |
| TW201729809A (en) | 2017-09-01 |
| AU2016375724A1 (en) | 2018-07-12 |
| CN108430474A (en) | 2018-08-21 |
| BR112018012903A2 (en) | 2018-12-11 |
| CA3009309A1 (en) | 2017-06-29 |
| EP3393476A1 (en) | 2018-10-31 |
| PH12018501315A1 (en) | 2019-02-18 |
| US20190008854A1 (en) | 2019-01-10 |
| JP2018538344A (en) | 2018-12-27 |
| MX2018007791A (en) | 2018-11-09 |
| KR20180097652A (en) | 2018-08-31 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| SG11201907034PA (en) | Methods of treating influenza | |
| SG11201808990QA (en) | Compositions for topical application of compounds | |
| SG11201809126RA (en) | Aromatic sulfonamide derivatives | |
| SG11201811470PA (en) | Pyrazolopyrimidine derivatives as kinase inhibitor | |
| SG11201407368VA (en) | Drug for preventing and/or treating polycystic kidney disease | |
| SG11201809908TA (en) | Stabilized glycopeptide antibiotic formulations | |
| SG11201408271VA (en) | Substituted pyrrolidines as factor xia inhibitors for the treatment thromboembolic diseases | |
| SG11201805363QA (en) | Drug comprising aripiprazole and cilostazol | |
| SG11201403402VA (en) | Compounds | |
| SG11201805368YA (en) | Anthelmintic depsipeptide compounds | |
| SG11201907804QA (en) | Pharmaceutical composition comprising selexipag | |
| SG11201908326YA (en) | Methods of treating neurodegenerative diseases | |
| SG11201809341PA (en) | Mobile robot | |
| SG11201808222RA (en) | Methods of treatment of cholestatic diseases | |
| SG11201809882XA (en) | Pharmaceutical combinations for treating cancer | |
| SG11201900558RA (en) | Spiro-lactam nmda receptor modulators and uses thereof | |
| SG11202000333UA (en) | Bicyclic ketone compounds and methods of use thereof | |
| SG11201809172WA (en) | Crystalline forms of n-[2-(3-hydroxy-3-methylbutyl)-6-(2-hydroxypropan-2-yl)-2h-indazol-5-yl]-6-(trifluoromethyl)pyridine-2-carboxamide | |
| SG11201903061YA (en) | Combination treatments comprising administration of imidazopyrazinones | |
| SG11201804587QA (en) | Isoindole compounds | |
| SG11201810078PA (en) | Stabilized pre-fusion rsv f proteins | |
| SG11201806393QA (en) | Use of gabaa receptor modulators for treatment of itch | |
| SG11201901850XA (en) | Dopamine-b-hydroxylase inhibitors | |
| SG11201807835RA (en) | An injector with reduced break loose force | |
| SG11201810934TA (en) | Microparticles comprising a sulphur-containing compound |